Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04211675 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Study acronym: STING
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Nationwide Children's Hospital to Nationwide Children's Hospital Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 4 entries
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Dec 2025 to Dec 2027
    • Site contact updated
    v12
  3. Primary completion date: Dec 2023 to Dec 2024v11
  4. Eligibility criteria shortened, about 3 wordsv10
  5. Eligibility criteria expanded, about 53 words
    • Secondary endpoints: details revised at 1 of 1 entry
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv8 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Study completion date: Dec 2024 to Dec 2025
    • Start date changed from estimate of Jun 2022 to Sep 1, 2022
    • Collaborators shortened, about 3 words
  2. Start date: Jun 2021 to Jun 2022v7
  3. Start date: Jan 2021 to Jun 2021v6
  4. Primary completion date: Dec 2022 to Dec 2023
    • Start date: Jun 2020 to Jan 2021
    • Study completion date: Dec 2023 to Dec 2024
    v5
  5. Start date: Apr 2020 to Jun 2020v4
  6. Start date: Jan 2020 to Apr 2020v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab. The phase 2 of the study will estimate the response to treatment.
Trial Details
NCT Number NCT04211675
Lead Sponsor Nationwide Children's Hospital
Conditions
(from sponsor)		 Relapsed Neuroblastoma, Refractory Neuroblastoma
Related terms Neuroblastoma
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov